TG Therapeutics Boosts 2026 BRIUMVI Revenue Target to $885M-$900M
summarizeSummary
TG Therapeutics has increased its full-year 2026 U.S. product revenue target for BRIUMVI to $885 million-$900 million. This represents an upward revision from the prior guidance of $875 million-$900 million, which was established in an 8-K filing on February 26, 2026. The adjustment, specifically raising the lower bound of the revenue range by $10 million, signals robust sales performance for BRIUMVI, a critical product for the company. This positive update to financial expectations is likely to be viewed favorably by the market, potentially bolstering investor sentiment and supporting the stock. Traders will be watching for continued momentum in BRIUMVI sales and any further guidance adjustments in upcoming financial reports.
At the time of this announcement, TGTX was trading at $36.50 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $5.8B. The 52-week trading range was $25.28 to $40.99. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Dow Jones Newswires.